Evidence map›Paper›PMID 37321669›Full record

ArticleRMD open2023

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.

Arsène Mekinian, Lucie Biard, Dagna Lorenzo, Pavel I Novikov, Carlo Salvarani, Olivier Espitia, Savino Sciascia, Martin Michaud, Marc Lambert, José Hernández-Rodríguez and 48 more

Erratum issuedOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

58 authors at 20 institutions in 8 countries.

Arsène MekinianSorbonne Université, AP-HP, Hôpital Saint Antoine, Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), F-75012, Paris, France, French Armenian research center, Erevan, Armenia arsene.mekinian@aphp.fr.ORCID 0000-0003-2849-3049
Lucie BiardUniversité de Paris, AP-HP, Hôpital Saint Louis, Service de Biostatistique et Information Médicale (DMU PRISME), INSERM U1153 Team ECSTRRA, Paris, France.
Dagna LorenzoUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.ORCID 0000-0002-7428-315X
Pavel I NovikovTareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Carlo SalvaraniAzienda USL-IRCCS; Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy.
Olivier EspitiaDepartment of internal and vascular medicine, Nantes Université, CHU Nantes, F-44000 Nantes, France.
Savino SciasciaCenter of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Aosta Valley Network for Rare Diseases, Nephrology and Dialysis, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Martin MichaudMédecine Interne, Hôpital Joseph Ducuing, Toulouse, France.
Marc LambertUniv. Lille, CHU Lille, Département de Médecine Interne et d'Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares Nord et Nord-Ouest de France (CeRAINO), European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNECT), INSERM, UMR 1167, RID-AGE, Lille, France.
José Hernández-RodríguezVasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Nicolas SchleinitzDépartement de médecine interne, CHU de La Timone, Marseille, France.
Abid AwisatRheumatology Unit, Bnei Zion Hospital, Haifa, Israel.
Xavier PuechalUniversité Paris Descartes, Paris, France ; AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, Service de médecine interne, 27 rue du Faubourg Saint-Jacques, Paris, France.ORCID 0000-0003-3573-9203
Achille AoubaDépartement de médecine interne, CHU Caen, Caen, France.
Helene Munoz PonsDépartement de médecine interne, CHU Saint Etienne, Saint-Etienne, France.
Ilya SmitienkoRheumatology Department, Medical Center K-31, Moscow, Russian Federation.
Jean Baptiste GaultierService de Médecine Interne, Hôpital Nord, Centre Hospitalier universitaire de St Etienne, Saint Etienne, France.
Le Mouel EdwigeInternal Medicine and Clinical Immunology Department, CHU Rennes, Universitaire de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
Ygal BenhamouService de médecine interne, Université Rouen, CHU de Rouen, Rouen, France.
Antoinette PerlatInternal Medicine and Clinical Immunology Department, CHU Rennes, Universitaire de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
Patrick JegoInternal Medicine and Clinical Immunology Department, CHU Rennes, Universitaire de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
Tiphaine GoulenokDépartement de Médecine Interne, Hôpital Bichat, Université de Paris, Assistance Publique Hôpitaux de Paris, INSERM U1149, Paris, France.
Karim SacreDépartement de Médecine Interne, Hôpital Bichat, Université de Paris, Assistance Publique Hôpitaux de Paris, INSERM U1149, Paris, France.ORCID 0000-0002-6544-234X
Bertrand LiogerService de médecine interne, CHU de Blois, Blois, France.
Nolan HassoldService de Rhumatologie pédiatrique et centre de référence des maladies autoinflammatoires et de l'amylose inflammatoire, CEREMAIA, hôpital de Bicêtre, APHP, France, université de Paris Sud-Saclay, Paris, France.
Jonathan BronerService de médecine interne, CHU de Nimes, Nimes, France.
Virginie DufrostVascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, University of Lorraine, Inserm UMR_S 1116, CHRU de Nancy, Nancy, France.
Thomas SenéService de médecine interne, Rothschild, Paris, France.ORCID 0000-0002-3162-2537
Julie SeguierDépartement de médecine interne, CHU de La Timone, Marseille, France.
Francois MaurierService de Médecine Interne et Immunologie Clinique Groupe Hospitalier UNEOS, Vantoux, France.
Sabine BerthierService de médecine interne et immunologie clinique, Université Dijon, Hôpital Dijon, Dijon, France.
Alexandre BelotService de pédiatrie et immunologie clinique, Université Lyon, Hôpital Lyon, Lyon, France.
Faten FrikhaService de Médecine interne CHU Hédi Chaker, Route El Ain 3029 Sfax -Faculté de Médecine de Sfax, Sfax, Tunisia.
Guillaume DenisService de médecine et d'hématologie, Hopital Rochefort, Rochefort, France.
Alexandra Audemard-VergerDepartment of Internal Medicine and Clinical Immunology, CHRU Tours, University of Tours, Tours, France.
Isabelle Koné-PautService de Rhumatologie pédiatrique et centre de référence des maladies autoinflammatoires et de l'amylose inflammatoire, CEREMAIA, hôpital de Bicêtre, APHP, France, université de Paris Sud-Saclay, Paris, France.ORCID 0000-0001-8939-5763
Sebastien HumbertService de médecine interne et immunologie clinique, Hôpital Besancon, Besancon, France.
Pascal Woaye-HuneService de médecine interne, Hôpital de la Réunion, Réunion, France.
Alessandro TomelleriUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.ORCID 0000-0002-5440-2078
Elena Marina BaldisseraUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Masataka KuwanaDepartment of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0001-8352-6136
Alberto Lo GulloRheumatology Unit, Arnas Garibaldi Hospital, Catania, Italy.
Vahan MukuchyanDepartment of Internal Medicine and Rheumatology, Nairi hospital, Erevan, Armenia.
Azeddine DellalService de rhumatologie, Hôpital Montfermeil, GHI Le Raincy Montfermeil, Montfermeil, France.
Francis GachesMédecine Interne, Hôpital Joseph Ducuing, Toulouse, France.
Pierre ZeminskyVascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, University of Lorraine, Inserm UMR_S 1116, CHRU de Nancy, Nancy, France.
Elena GalliUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Moya AlvaradoAzienda USL-IRCCS; Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy.
Luigi BoiardiAzienda USL-IRCCS; Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy.
Francesco MuratoreAzienda USL-IRCCS; Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy.ORCID 0000-0003-0362-2668
Mathieu VautierUniversité de Paris, AP-HP, Hôpital Saint Louis, Service de Biostatistique et Information Médicale (DMU PRISME), INSERM U1153 Team ECSTRRA, Paris, France.
Corrado CampochiaroUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.ORCID 0000-0001-6806-3794
Sergey MoiseevTareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Matheus VieiraAP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Universités, Paris, France.
Patrice CacoubAP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Universités, Paris, France.
Olivier FainSorbonne Université, AP-HP, Hôpital Saint Antoine, Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), F-75012, Paris, France, French Armenian research center, Erevan, Armenia.
David SaadounAP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Universités, Paris, France.
French Takayasu network
Inserm · FRSorbonne Université · FRVita-Salute San Raffaele University · ITUniversity of Modena and Reggio Emilia · ITUniversité Claude Bernard Lyon 1 · FRHôpital de la Timone · FRHôpital Joseph-Ducuing · FRSechenov University · RUUniversité Paris-Saclay · FRBnai Zion Medical Center · ILCentre Hospitalier de Rochefort · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Caen Normandie · FRCentre Hospitalier Universitaire de La Réunion · FRCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Nîmes · FRCentre Hospitalier Universitaire de Rouen · FRCentre Hospitalier Universitaire de Saint-Étienne · FREuropean Organisation for Rare Diseases · FRGroupe Hospitalier Intercommunal Le Raincy Montfermeil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.

methodsWe conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019.

resultsA total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab.

conclusionIn this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months.

Indexed as

Antirheumatic AgentsTakayasu ArteritisAdultAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedAntirheumatic AgentstocilizumabAutoimmune DiseasesInflammationSystemic vasculitis

Identifiers

PMID37321669
PMCPMC10277523
OpenAlexW4380869701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.